A BILL 
To improve reporting of the distribution of controlled 
substances, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Suspicious Order Iden-
4
tification Act of 2019’’. 
5
SEC. 2. STRENGTHENING ARCOS. 
6
Section 307(d) of the Controlled Substances Act (21 
7
U.S.C. 827(d)) is amended to read as follows: 
8
19:41 Oct 31, 2019
H4814
2 
•HR 4814 IH
‘‘(1)(A) Every registrant under section 303 shall and 
1
in such form as the Attorney General may require, make 
2
reports in electronic format to the Attorney General of 
3
every sale, delivery, or other disposal (other than by dis-
4
pensing by a practitioner) by the registrant of any con-
5
trolled substance, identifying by the registration number 
6
assigned under this title the person or establishment (un-
7
less exempt from registration under section 302(d)) to 
8
whom such sale, delivery, or other disposal was made. 
9
‘‘(B) Every registrant shall make each report re-
10
quired under subparagraph (A)— 
11
‘‘(i) not later than 30 days after the sale, deliv-
12
ery, or other disposal; or 
13
‘‘(ii) after the date on which the real-time re-
14
porting system is established under section 3(e)(3) 
15
of the Suspicious Order Identification Act of 2019 
16
is implemented, in real time.’’. 
17
SEC. 3. SUSPICIOUS ORDERS TASK FORCE. 
18
(a) DEFINITIONS.—In this section: 
19
(1) ADMINISTRATOR.—The term ‘‘Adminis-
20
trator’’ means the Administrator of the Drug En-
21
forcement Administration. 
22
(2) CONTROLLED
SUBSTANCE; DISTRIBUTOR; 
23
MANUFACTURER.—The 
terms 
‘‘controlled 
sub-
24
stance’’, ‘‘distributor’’, and ‘‘manufacturer’’ have the 
25
19:41 Oct 31, 2019
H4814
3 
•HR 4814 IH
meanings given those terms in section 102 of the 
1
Controlled Substances Act (21 U.S.C. 802). 
2
(3) REAL TIME.—The term ‘‘real time’’ means 
3
with as little delay as technically and economically 
4
feasible, as determined by the Attorney General fol-
5
lowing the program designed under subsection 
6
(e)(1), but not to exceed 24 hours. 
7
(4) REGISTRANT.—The term ‘‘registrant’’— 
8
(A) means a person registered under sec-
9
tion 303 of the Controlled Substances Act (21 
10
U.S.C. 823); and 
11
(B) does not include practitioner. 
12
(b) ESTABLISHMENT.—The Attorney General, in 
13
consultation with the Director of the Office of National 
14
Drug Control Policy and the Secretary of Health and 
15
Human Services, shall establish a Suspicious Order Moni-
16
toring Task Force (referred to in this section as the ‘‘Task 
17
Force’’). 
18
(c) COMPOSITION.— 
19
(1) IN
GENERAL.—The Task Force shall be 
20
composed of appropriate personnel from— 
21
(A) the Department of Justice; 
22
(B) the Drug Enforcement Administration; 
23
(C) the Office of National Drug Control 
24
Policy; 
25
19:41 Oct 31, 2019
H4814
4 
•HR 4814 IH
(D) the National Institute of Standards 
1
and Technology; and 
2
(E) other appropriate Federal, State, and 
3
local law enforcement and regulatory agencies 
4
with experience in investigating and prosecuting 
5
illegal transactions of controlled substances as 
6
determined by the Attorney General, in con-
7
sultation with the Secretary of Health and 
8
Human Services. 
9
(2) CONSULTANTS.—The Task Force shall con-
10
sult with— 
11
(A) industry members, including— 
12
(i) data analytic professionals; 
13
(ii) community pharmacies that dis-
14
pense controlled substances; 
15
(iii) chain pharmacies that dispense 
16
controlled substances; 
17
(iv) distributors of controlled sub-
18
stances; 
19
(v) manufacturers of controlled sub-
20
stances; 
21
(vi) State and local public health offi-
22
cials; and 
23
(vii) other relevant industry profes-
24
sionals; and 
25
19:41 Oct 31, 2019
H4814
5 
•HR 4814 IH
(B) relevant industry regulators and enti-
1
ties that utilize real-time reporting of trans-
2
actions, orders, or other activities with the goal 
3
of identifying suspicious activity, such as appro-
4
priate personnel from the Financial Crimes En-
5
forcement Network and money transfer indus-
6
try professionals. 
7
(d) MEETINGS.— 
8
(1) IN GENERAL.—The Task Force shall meet 
9
not less frequently than 4 times per year and at 
10
such other times as may be determined necessary by 
11
the Task Force. 
12
(2) INITIAL MEETING.—Not later than 60 days 
13
after the date of enactment of this Act, the Task 
14
Force shall hold the initial meeting of the Task 
15
Force. 
16
(e) PRELIMINARY ORDER EVALUATION PROGRAM.— 
17
(1) IN GENERAL.— 
18
(A) DESIGN.—Not later than 60 days after 
19
the date on which the Task Force holds the ini-
20
tial meeting required under subsection (d)(2), 
21
the Task Force shall begin to design a program 
22
in accordance with paragraph (2). 
23
(B) PURPOSE.—The program described in 
24
subparagraph (A) shall be designed to share 
25
19:41 Oct 31, 2019
H4814
6 
•HR 4814 IH
necessary data, in a limited capacity, with reg-
1
istrants in order to provide registrants with in-
2
formation to identify suspicious ordering in real 
3
time. 
4
(C) DEADLINE
FOR
COMPLETION.—Not 
5
later than 8 months after the date of enactment 
6
of this Act, the Task Force shall complete the 
7
design required under subparagraph (A). 
8
(2) REQUIREMENTS.— 
9
(A) IN GENERAL.—The program required 
10
under paragraph (1) shall establish a process 
11
for— 
12
(i) transitioning to a requirement to 
13
report in real time to the Attorney General 
14
under section 307(d) of the Controlled 
15
Substances Act (21 U.S.C. 827(d)) every 
16
sale, delivery, or other disposal by a reg-
17
istrant of any controlled substance; 
18
(ii) limited sharing in real time of Au-
19
tomation of Reports and Consolidated Or-
20
ders 
System 
(commonly 
known 
as 
21
‘‘ARCOS’’) data with registrants to share 
22
necessary data, in a limited capacity, with 
23
registrants in order to provide registrants 
24
19:41 Oct 31, 2019
H4814
7 
•HR 4814 IH
with information to identify suspicious or-
1
dering in real time; and 
2
(iii) ensuring data privacy, data de- 
3
identification, protection of trade secrets 
4
and purchasing history. 
5
(B) OTHER CONSIDERATIONS.—In design-
6
ing the program under paragraph (1), the Task 
7
Force shall take into consideration— 
8
(i) the inclusion of a waiver process 
9
for pharmacies and other registrants un-
10
able to transmit orders electronically on 
11
the date of enactment of this Act; 
12
(ii) a mechanism to ensure that the 
13
costs of running the program are not 
14
passed through to customers of registrants, 
15
unless the registrants are customers of 
16
other registrants; 
17
(iii) technical requirements for ensur-
18
ing that registrants may access all relevant 
19
de-identified data, with output provided in 
20
a standard database file format; and 
21
(iv) a mechanism to ensure that the 
22
program required to be designed under 
23
subparagraph (A) is updated based on 
24
19:41 Oct 31, 2019
H4814
8 
•HR 4814 IH
feedback from industry members and other 
1
relevant entities. 
2
(3) IMPLEMENTATION.—Not later than 1 year 
3
after the date of enactment of this Act, the Attorney 
4
General shall— 
5
(A) implement the program designed under 
6
paragraph (1) to collect and share in real time 
7
data for registrants to evaluate the orders of 
8
controlled substances from distributors to man-
9
ufacturers and from pharmacies to distributors; 
10
or 
11
(B) otherwise implement a program to col-
12
lect and share in real time data for drug manu-
13
facturers and distributors, by providing access 
14
to anonymized information to help drug manu-
15
facturers and distributors identify, report, and 
16
stop suspicious orders of controlled substances 
17
and reduce diversion rates. 
18
(4) RECOMMENDED
STATUTORY
AND
REGU-
19
LATORY CHANGES.—In designing the program re-
20
quired under paragraph (1), the Task Force— 
21
(A) shall submit to the Attorney General 
22
any recommendations for necessary amend-
23
ments to regulations of the Department of Jus-
24
tice relating to the requirements for ordering 
25
19:41 Oct 31, 2019
H4814
9 
•HR 4814 IH
schedule II controlled substances, so as to allow 
1
uniform electronic ordering of controlled sub-
2
stances in schedules II, III, IV, and V electroni-
3
cally through the program; and 
4
(B) may submit to Congress any rec-
5
ommendations for necessary legislative changes 
6
so that a real-time data analytics solution can 
7
be used across the United States. 
8
(5) RESPONSIBILITY
OF
REGISTRANTS.—All 
9
registered drug manufacturers and distributors shall 
10
be responsible for reviewing any information made 
11
available by the Attorney General and complying 
12
with any regulations regarding the program designed 
13
under paragraph (1) and implemented under para-
14
graph (3). 
15
(f) FUNDING.— 
16
(1) IN GENERAL.—The Attorney General, act-
17
ing through the Administrator, shall use amounts 
18
collected as fees for distributors and registrants 
19
under section 303 of the Controlled Substances Act 
20
(21 U.S.C. 823) and section 1007 of the Controlled 
21
Substances Import and Export Act (21 U.S.C. 957) 
22
to carry out this section. 
23
(2) OFFSET.— 
24
19:41 Oct 31, 2019
H4814
10 
•HR 4814 IH
(A) IN
GENERAL.—The Administrator 
1
may, on an equal basis and in accordance with 
2
subparagraph (B), increase the fees described 
3
in paragraph (1) for distributors and reg-
4
istrants to the extent necessary to defray the 
5
costs of this section. 
6
(B) TIERED
FEE.—The Administrator 
7
shall establish a tiered user fee for distributors 
8
and registrants in proportion to the volume of 
9
sales and purchases. 
10
(g) APPLICABILITY OF FACA.— 
11
(1) IN GENERAL.—Except as provided in para-
12
graph (2), the Federal Advisory Committee Act (5 
13
U.S.C. App.) shall apply to the Task Force. 
14
(2) TERMINATION.—The Task Force shall ter-
15
minate on the date on which the program is fully 
16
implemented under subsection (e)(3). 
17
(h) RULES OF CONSTRUCTION.—Nothing in this Act 
18
shall be construed as relieving any manufacturer, dis-
19
tributor, or other registrant from the responsibilities of 
20
the manufacturer, distributor, or other registrant, as the 
21
case may be, to— 
22
(1) identify, stop, and report suspicious orders; 
23
19:41 Oct 31, 2019
H4814
11 
•HR 4814 IH
(2) maintain effective controls against diversion 
1
in accordance with section 303 of the Controlled 
2
Substances Act (21 U.S.C. 823); and 
3
(3) comply with the requirements established in 
4
section 1301.74(b) of title 21, Code of Federal Reg-
5
ulations, or any successor regulation thereto, with 
6
respect to suspicious orders. 
7
Æ 
19:41 Oct 31, 2019
H4814
